Adrian Brink

Summary

Affiliation: Milpark Hospital
Country: South Africa

Publications

  1. ncbi Appropriate use of the carbapenems
    A J Brink
    Ampath, Johannesburg
    S Afr Med J 94:857-61. 2004
  2. doi Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics
    Adrian J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Suite 9C, Milpark Hospital, 9 Guild Road, Parktown West, 2193 Johannesburg, South Africa Electronic address
    Int J Antimicrob Agents 43:1-6. 2014
  3. pmc Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract
    Adrian J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa
    J Clin Microbiol 51:369-72. 2013
  4. ncbi The spread of carbapenem-resistant Enterobacteriaceae in South Africa: risk factors for acquisition and prevention
    Adrian Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa
    S Afr Med J 102:599-601. 2012
  5. doi Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints
    Adrian J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Parktown, Johannesburg, South Africa
    Surg Infect (Larchmt) 13:43-9. 2012
  6. ncbi Guideline summary: appropriate use of tigecycline
    A J Brink
    Ampath National Laboratory Services, Milpark Hospital, Johannesburg
    S Afr J Surg 50:20-1. 2012
  7. pmc Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa
    Adrian J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa
    J Clin Microbiol 50:525-7. 2012
  8. ncbi Guideline: appropriate use of tigecycline
    A J Brink
    Ampath National Laboratory Services
    S Afr Med J 100:388-94. 2010
  9. doi Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis
    A J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa
    Int J Antimicrob Agents 33:432-6. 2009
  10. ncbi Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer
    Adrian Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg
    S Afr Med J 98:586, 588, 590 passim. 2008

Collaborators

Detail Information

Publications18

  1. ncbi Appropriate use of the carbapenems
    A J Brink
    Ampath, Johannesburg
    S Afr Med J 94:857-61. 2004
    ..This statement arises out of concerns about the general abuse of antibiotics such as the carbapenems, with the primary intention of highlighting the appropriate use of these agents...
  2. doi Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics
    Adrian J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Suite 9C, Milpark Hospital, 9 Guild Road, Parktown West, 2193 Johannesburg, South Africa Electronic address
    Int J Antimicrob Agents 43:1-6. 2014
    ....
  3. pmc Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract
    Adrian J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa
    J Clin Microbiol 51:369-72. 2013
    ....
  4. ncbi The spread of carbapenem-resistant Enterobacteriaceae in South Africa: risk factors for acquisition and prevention
    Adrian Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa
    S Afr Med J 102:599-601. 2012
    ....
  5. doi Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints
    Adrian J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Parktown, Johannesburg, South Africa
    Surg Infect (Larchmt) 13:43-9. 2012
    ....
  6. ncbi Guideline summary: appropriate use of tigecycline
    A J Brink
    Ampath National Laboratory Services, Milpark Hospital, Johannesburg
    S Afr J Surg 50:20-1. 2012
    ....
  7. pmc Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa
    Adrian J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa
    J Clin Microbiol 50:525-7. 2012
    ..NDM-1 producers have not been described in South Africa, and this is the first instance that KPC producers have been identified in Africa. The two patients infected with these carbapenemase-producing bacteria demised...
  8. ncbi Guideline: appropriate use of tigecycline
    A J Brink
    Ampath National Laboratory Services
    S Afr Med J 100:388-94. 2010
    ....
  9. doi Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis
    A J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa
    Int J Antimicrob Agents 33:432-6. 2009
    ..This raises the question as to whether ertapenem is an appropriate agent for initial use in critically ill patients with severe sepsis...
  10. ncbi Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer
    Adrian Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg
    S Afr Med J 98:586, 588, 590 passim. 2008
  11. doi Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis
    A J Brink
    Department of Clinical Microbiology, Ampath National Laboratory Services, Johannesburg, Gauteng, South Africa
    Int J Antimicrob Agents 32:455-8. 2008
    ..Regarding the latter infections, higher loading doses might be warranted to reach rapid steady-state concentrations...
  12. ncbi Antimicrobial susceptibility profile of selected bacteraemic pathogens from private institutions in South Africa
    Adrian Brink
    Department of Clinical Microbiology, Ampath Laboratories, Johannesburg, South Africa
    S Afr Med J 97:273-9. 2007
    ..The National Antimicrobial Surveillance Forum is a continuous surveillance organisation comprising all academic/public and private sector laboratories in South Africa...
  13. ncbi Guideline for the management of nosocomial infections in South Africa
    Adrian Brink
    S Afr Med J 96:642-52. 2006
    ....
  14. pmc An unusual pneumococcal sequence type is the predominant cause of serotype 3 invasive disease in South Africa
    Kedibone M Mothibeli
    Respiratory and Meningeal Pathogens Research Unit, National Institute for Communicable Diseases, Medical Research Council, University of the Witwatersrand, Johannesburg, South Africa
    J Clin Microbiol 48:184-91. 2010
    ..We have therefore identified ST458 as predominating in South Africa, but with an invasive potential similar to that of the predominant global clone ST180...
  15. doi Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa
    Cheryl Cohen
    National Institute for Communicable Diseases, Johannesburg, South Africa
    AIDS 24:1351-60. 2010
    ..We aimed to compare the incidence of meningococcal disease amongst HIV-infected and uninfected individuals and to evaluate whether HIV is a risk factor for mortality and bacteremia amongst patients with meningococcal disease...
  16. pmc Neisseria meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001 to 2005
    Mignon du Plessis
    National Institute for Communicable Diseases of the National Health Laboratory Service, University of the Witwatersrand, Johannesburg, South Africa
    J Clin Microbiol 46:3208-14. 2008
    ..This is the first report describing the prevalence and molecular epidemiology of Pen(i) meningococcal isolates from sub-Saharan Africa...
  17. doi Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study
    Anne Von Gottberg
    National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
    Lancet 371:1108-13. 2008
    ..Our aim was to estimate the incidence of, and risk factors for, invasive pneumococcal disease caused by fluoroquinolone-resistant Streptococcus pneumoniae in children in South Africa...
  18. doi Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000-2005
    Nicole Wolter
    Respiratory and Meningeal Pathogens Research Unit, National Institute for Communicable Diseases, Medical Research Council and University of the Witwatersrand, Sandringham, South Africa
    Int J Antimicrob Agents 32:62-7. 2008
    ..Routine use of the 7-valent pneumococcal conjugate vaccine (PCV-7) could reduce the burden of macrolide-resistant pneumococcal disease in South Africa...